Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

  NCT04504669· AstraZeneca· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Epidemiological characteristics of cervical cancer in Asian populations and risk factor inference based on Mendelian randomization.

  Medicine (Baltimore), 2026. okt.

• Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs.

  Medicine (Baltimore), 2026. szept.

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, 2026. júl.

• Bidirectional mendelian randomization identifies plasma proteins associated with cervical cancer risk.

  J Egypt Natl Canc Inst, 2026. júl.

• Cervical cancer mortality trends and inequities, 1999 to 2023: Joinpoint and spatial analyses integrated with two-sample Mendelian randomization.

  Medicine (Baltimore), 2026. máj.

• Absence of causal association between CD40-CD40L signaling and cervical cancer risk: A Mendelian randomization study.

  Medicine (Baltimore), 2026. máj.

• Immune Cells and Risk of Cervical Cancer: Evidence from a Mendelian Randomization Study.

  Clin Lab, 2026. ápr.

• The causal effect of cytokine cycling levels on the risk of cervical cancer: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. febr.

• Heavy metal exposure and cancer risk: Findings from a Mendelian randomization study.

  Toxicol Lett, 2026. febr.

• Investigating the relationship between taste perception of artificial sweeteners and cancer risk.

  Public Health Nutr, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.